Immunogen (IMGN) Misses Q1 EPS by 2c, Maintains FY Guidance

Immunogen (NASDAQ: IMGN) reported Q1 EPS of ($0.17), $0.02 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $13.3 million versus the consensus estimate of $14.94 million.

GUIDANCE:

Immunogen sees Q2 2020 revenue of $60-65 million, versus the consensus of $62.72 million.

• operating expenses between $165 million and $170 million; and
• cash and cash equivalents at December 31, 2020 to be between $170 million and $175 million.

For earnings history and earnings-related data on Immunogen (IMGN) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Seacoast Banking Corporation of Florida (SBCF) Tops Q1 EPS by 2c
• Edwards Lifesciences (EW) Tops Q1 EPS by 2c; offers guidance